Longeveron Inc.
LGVN
Positions held
Your positionsLGVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $7.56M | Enterprise value | -$1.94M | Trailing P/E | — | Forward P/E | -1.55 |
| PEG | — | Price / book | 0.72 | Beta | -0.20 | Dividend yield | 0.00% |
| Revenue growth | -9.2% | Earnings growth | — | Gross margin | 69.8% | Operating margin | -21.5% |
| Profit margin | 0.0% | ROE | -2.0% | ROA | -90.9% | Debt / equity | 0.06 |
| Current ratio | 2.63 | Free cash flow | -$11.60M | Analyst recommendation | none | Mean target | $61.25 |
| 52w high | $12.30 | 52w low | $2.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | $0.4M | $0.4M | $0.1M | $0.3M | — |
| Op margin | -2150.2% | -1199.7% | -1479.2% | -5335.8% | -1707.9% | — |
| Net income | -$6.1M | -$4.7M | -$5.4M | -$7.2M | -$5.0M | — |
| Gross margin | 63.4% | 66.3% | 70.4% | 91.2% | 46.2% | — |
| Gross profit | $0.2M | $0.3M | $0.3M | $0.1M | $0.1M | — |
| Operating income | -$6.2M | -$4.8M | -$5.4M | -$7.3M | -$5.4M | — |
- Revenue -28% vs prior quarter ($0.3M vs $0.4M).
- Gross margin 63.4% (was 66.3% prior quarter).
- Operating margin compressed to -2150.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $0.7M | $1.2M | — |
| Op margin | -1942.2% | -690.7% | -2966.0% | -1476.5% | — |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | — |
| Gross margin | 67.0% | 78.8% | 31.2% | 40.7% | — |
| Gross profit | $0.8M | $1.9M | $0.2M | $0.5M | — |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Longeveron to Participate in Three Longevity/Aging Investment Conferences
2026-09-22 · Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
2026-09-18 · Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
2026-09-17 · Top Midday Decliners
2026-09-17 · LGVN Posts Disappointing Trial Results
2026-09-16 · Longeveron Shares Halted After Heart Therapy Trial Misses Primary Endpoint
2026-09-03 · Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-24 · Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-24 · Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-19 · Longeveron (LGVN) Q2 2026 Earnings Call Transcript
2026-08-19 · Longeveron Appoints Nirav Jhaveri As CFO
Price (daily)
Full chart · RSI · MACD · patterns